In Current research in translational medicine
BACKGROUND : Since dementia is preventable with early interventions, biomarkers that assist in diagnosing early stages of dementia, such as mild cognitive impairment (MCI), are urgently needed.
METHODS : Multiomics analysis of amnestic MCI (aMCI) peripheral blood (n = 25) was performed covering the transcriptome, microRNA, proteome, and metabolome. Validation analysis for microRNAs was conducted in an independent cohort (n = 12). Artificial intelligence was used to identify the most important features for predicting aMCI.
FINDINGS : We found that hsa-miR-4455 is the best biomarker in all omics analyses. The diagnostic index taking a ratio of hsa-miR-4455 to hsa-let-7b-3p predicted aMCI patients against healthy subjects with 97% overall accuracy. An integrated review of multiomics data suggested that a subset of T cells and the GCN (general control nonderepressible) pathway are associated with aMCI.
INTERPRETATION : The multiomics approach has enabled aMCI biomarkers with high specificity and illuminated the accompanying changes in peripheral blood. Future large-scale studies are necessary to validate candidate biomarkers for clinical use.
Tatara Yota, Yamazaki Hiromi, Katsuoka Fumiki, Chiba Mitsuru, Saigusa Daisuke, Kasai Shuya, Nakamura Tomohiro, Inoue Jin, Aoki Yuichi, Shoji Miho, Motoike Ikuko N, Tamada Yoshinori, Hashizume Katsuhito, Shoji Mikio, Kinoshita Kengo, Murashita Koichi, Nakaji Shigeyuki, Yamamoto Masayuki, Itoh Ken
2022-Oct-22
Biomarker, Cohort, Metabolome, “Mild cognitive impairment, Alzheimers disease with dementia”, Proteome, Regulatory T cells, Transcriptome, miRNA
